



EHA 2025 Congress

June 12–15, 2025
Milan, Italy



TOP ABSTRACTS

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

EHA 2025: Top abstracts in ALL

June 12–15, 2025

Thursday, June 12, 2025			
Abstract	Title	Speaker	Time CEST
S271 View	The B-ALL stromal landscape: Spatial organization and functional specialization of distinct niche subtypes	Mauricio Ferrao Blanco	17:15–17:30
Friday, June 13, 2025			
Abstract	Title	Speaker	Time CEST
S115 View	Advancing chemogenomic strategies for functional precision medicine in relapsed/refractory T-ALL and ETP-ALL: Preliminary results of the GIMEMA ALL2720 trial	Luca Pagliaro	17:00–17:15
S116 View	Achievement of MRD negativity after end of induction with ponatinib and imatinib in the phase III PhALLCON trial: A post hoc analysis	Carlo Gambacorti-Passerini	17:15–17:30
S117 View	Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: Early results from the phase I/II SYRUS study	Ibrahim Aldoss	17:30–17:45
S118 View	Long-term follow-up of an intensive pediatric regimen for adolescents/young adults (AYA) with acute lymphoblastic leukemia (ALL): 10-year survival following CALGB 10403 (ALLIANCE)	Wendy Stock	17:45–18:00
S304 View	Invasive fungal infections in acute lymphoblastic leukemia: Preliminary results of a multicentric prospective SEIFEM study (ALL-IFI)	Chiara Cattaneo	18:00–18:15
PF348 View	Optimizing asparaginase hypersensitivity management: Real-world evidence on asparaginase switching practices and guideline adherence	Luke Maese	18:30
PF374 View	Five-year survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3	Olalekan Oluwole	18:30
PF377 View	Real-world effectiveness and safety in adults with minimal residual disease-positive or relapsed/refractory B-cell acute lymphoblastic leukaemia treated with blinatumomab across 13 European countries	Sabina Chiaretti	18:30
PF378 View	Predicting hematotoxicity risk and outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Should hematotox models be CAR specific rather than disease specific	Elias Jabbour	18:30

Friday, June 13, 2025 (continued)			
Abstract	Title	Speaker	Time CEST
PF381 View	Performance of blinatumomab for MRD treatment and bridge to allo-SCT in Ph-negative B-ALL patients treated with pediatric inspired LAL1913 program (subanalysis of the CAMPUS-ALL LAL1913 study).	Anna Candoni	18:30
PF384 View	Frontline chemotherapy-free combination of olverembatinib with venetoclax and azacitidine in newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study	Xiaowen Tang	18:30
PF386 View	A prospective study of flumatinib with chemotherapy for newly diagnosed <i>BCR::ABL1</i> -positive acute lymphoblastic leukemia in adults: RJ-ALL2020.2A trial	Weiyang Liu	18:30
PF388 View	Integrated venetoclax with immunochemotherapy in older or unfit patients with newly diagnosed Philadelphia-negative B-cell acute lymphoblastic leukemia (B-ALL): A phase II multi-center clinical trial	Ying Wang	18:30
PF393 View	Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation	David Marks	18:30
PF401 View	Real world analysis of outcomes using a modified DFCI protocol for adults with <i>BCR-ABL</i> negative acute lymphoblastic leukemia - impact of MRD	Joseph Brandwein	18:30
PF403 View	KTE-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: A phase II multicenter study	Meng Lv	18:30
PF1089 View	Outcomes of blinatumomab added to conditioning regimen of allogeneic hematopoietic stem cell transplantation for adult B-cell acute lymphoblastic leukemia patient with low minimal residual disease	Jian Yu	18:30
PF1161 View	Inotuzumab-based protocols are safe and effective in patients with relapsed/refractory B-acute lymphoblastic leukemia planned for CD19 CAR-T cell therapy	Anupa John	18:30

Saturday, June 14, 2025

Abstract	Title	Speaker	Time CEST
PS1341 View	Efficacy of novel targeted therapies in Down syndrome acute lymphoblastic leukaemia	Kunjal Panchal	18:30
PS1367 View	Efficacy and safety of regimen with olverembatinib and blinatumomab for the frontline treatment of Ph-positive or Ph-like acute lymphoblastic leukemia	Xiuli Xu	18:30
PS1371 View	Inotuzumab ozogamicin in pediatric CD22-positive very high risk first relapse B-cell precursor acute lymphoblastic leukemia: Preliminary results of the ITCC-059 study	Erica Brivio	18:30
PS1372 View	Combination of olverembatinib and VP Regimen as first-line therapy for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-arm, multicentre, phase II trial	Gaixiang Xu	18:30
PS1376 View	Pegaspargase administration in acute lymphoblastic leukemia patients aged 55 years or older treated with the pediatric-inspired program LAL1913. A subanalysis of the CAMPUS ALL study	Davide Lazzarotto	18:30
PS1377 View	Multicenter real-world study on inotuzumab as a bridge to cellular therapy in relapsed/refractory B-cell acute lymphoblastic leukemia	Alicia Aguirre	18:30
PS1379 View	Comparative efficacy of the GIMEMA LAL1913 standard chemotherapy protocol versus the standard arm of the E1910 trial IN MRD-negative Ph-negative ALL: A MAIC analysis	Alfonso Piciocchi	18:30
PS1387 View	Efficacy and safety of the third-generation tyrosine kinase inhibitor olverembatinib in combination with inotuzumab ozogamicin for the treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients with relapsed disease or persistent minimal residual disease bridging to hematopoietic stem cell transplantation: A phase II study	Xiaoyu Zhang	18:30
PS1394 View	Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by body mass index	Wendy Stock	18:30
PS1473 View	Updated results and longer follow-up from the AUGMENT-101 phase II study of revumenib in patients with relapsed or refractory (R/R) <i>KMT2AR</i> acute leukemia	Ibrahim Aldoss	18:30
PS1926 View	A CAMPUS ALL retrospective multicenter study on the outcome of adult lymphoblastic lymphoma patients treated in the real-life according to the GIMEMA LAL1913 protocol	Mario Delia	18:30
PS2281 View	Health-related quality of life benefits of frontline ponatinib plus blinatumomab in adult patients with Ph+ acute lymphoblastic leukemia. Preliminary analysis of the GIMEMA ALL2820 trial	Laura Cannella	18:30

Sunday, June 15, 2025

Abstract	Title	Speaker	Time CEST
S110 View	Addition of blinatumomab to consolidation therapy for younger adults (<i>BCR:ABL1</i> -negative B-acute lymphoblastic leukemia (ALL) on the ECOG-ACRIN E1910 phase III trial	Shira Dinner	11:00–11:15
S111 View	Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by cumulative dose	Elias Jabbour	11:15–11:30
S112 View	Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase I/II dose expansion study	Elias Jabbour	11:30–11:45
S113 View	Can CAR T-cell therapy be a definitive treatment for adult R/R B-ALL without transplant? Long-term findings and predictors of sustained remission for obecabtagene autoleucel	Jae H. Park	11:45–12:00
S114 View	Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)	Bijal D. Shah	12:00–12:15



#EHA2025

Follow us on X to keep up to date
with the latest from the congress

@ALL_Hub_



ALLHub

Brought to you by



SES